Mankind Pharma Intrinsic Value
Mankind Pharma (MANKIND) median intrinsic value is ₹4154.80 from 9 valuation models (range ₹623–₹5194), vs current price ₹2077.40 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. For current market price and key ratios, visit MANKIND stock live price.
MANKIND Valuation Methods Summary — DCF, Graham Number & P/E
Mankind Pharma intrinsic value across 9 models vs current price ₹2077.40 — upside/downside and value range per method. Browse MANKIND income statement for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1090.32 | ₹872.26 - ₹1308.38 | -47.5% | EPS: ₹49.56, Sector P/E: 22x |
| Book Value Method | asset | ₹5193.50 | ₹4674.15 - ₹5712.85 | +150.0% | Book Value/Share: ₹3553.17, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹4154.80 | ₹3739.32 - ₹4570.28 | +100.0% | Revenue/Share: ₹3698.54, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹4154.80 | ₹3739.32 - ₹4570.28 | +100.0% | EBITDA: ₹4064.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹5193.50 | ₹4154.80 - ₹6232.20 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹623.22 | ₹560.90 - ₹685.54 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹765.70 | ₹689.13 - ₹842.27 | -63.1% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹4154.80 | ₹3739.32 - ₹4570.28 | +100.0% | ROE: 14.3%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹1990.51 | ₹1791.46 - ₹2189.56 | -4.2% | EPS: ₹49.56, BVPS: ₹3553.17 |
MANKIND Intrinsic Value vs Market Price — All Valuation Models
Mankind Pharma fair value range ₹623–₹5194 vs current market price ₹2077.40 across 9 valuation models. Compare with MANKIND fundamental valuation to assess whether the stock is under or overvalued.
MANKIND Intrinsic Value Analysis — Undervalued or Overvalued?
Mankind Pharma median intrinsic value ₹4154.80, current price ₹2077.40 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of MANKIND?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Mankind Pharma (MANKIND) is ₹4154.80 (median value). With the current market price of ₹2077.40, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹623.22 to ₹5193.50, indicating ₹623.22 - ₹5193.50.
Is MANKIND undervalued or overvalued?
Based on our multi-method analysis, Mankind Pharma (MANKIND) appears to be trading below calculated value by approximately 100.0%.
MANKIND Financial Health — Key Ratios vs Industry Benchmarks
Mankind Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.93 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 14.3% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 25.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.55x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
MANKIND Cash Flow Quality — Operating & Free Cash Flow
Mankind Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹2,413 Cr | ₹-3,899 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹2,152 Cr | ₹1,112 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹1,813 Cr | ₹1,287 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹920 Cr | ₹236 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹1,137 Cr | ₹526 Cr | Positive Free Cash Flow | 7/10 |